原文发表于美国时间2024-8-12
生物医药投资公司皇家医药公司（股票代码：RPRX）在今日上午有500份将于2025年1月17日到期的看涨期权以0.10美元的交易价格成交。
今天上午交易时，皇家医药公司的未平仓合约少于20份，故而上述交易是开仓交易。
皇家医药公司的股价在交易时为每股26.38美元。该公司看涨期权的delta值为5，故而这笔交易相当于2500股股票。
目前尚不清楚交易者是在针对已建立的股票头寸出售备兑看涨期权，还是在皇家医药公司的期权到期前投机价格会大幅上涨。
皇家医药公司股票目前的交易价格为每股26.68美元。该公司股票的52周高点为31.66美元，52周低点为25.20美元。
资料来源：IBKR交易者工作站。过去的表现并不预示未来的结果。
—
懂行的，选盈透！
这篇文章已被翻译成中文。原英文作者Jeff Praissman。如英文版本和中文版本之间有任何不一致，以英文版本为准。该文章中的分析仅为提供信息，不是也不应该被视为推销或招揽购买任何证券。文章中讨论的一般市场活动、行业或领域趋势、或其它基于广泛的经济或政治条件的内容，不应被解释为研究结果或投资建议。讨论中提及包括的特定证券、商品、货币、或其它产品均不构成IB推荐购买，出售或持有此类投资的建议。本材料不是也不意图针对个别客户的特定财务条件、投资目标或要求。在根据本材料采取行动之前，您应该考虑是否适合您的具体情况，并在必要时寻求专业建议。
DISCLOSURE: INTERACTIVE BROKERS
The analysis in this material is provided for information only and is not and should not be construed as an offer to sell or the solicitation of an offer to buy any security. To the extent that this material discusses general market activity, industry or sector trends or other broad-based economic or political conditions, it should not be construed as research or investment advice. To the extent that it includes references to specific securities, commodities, currencies, or other instruments, those references do not constitute a recommendation by IBKR to buy, sell or hold such investments. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Interactive Brokers LLC, its affiliates, or its employees.
Any trading symbols displayed are for illustrative purposes only and are not intended to portray recommendations.
In accordance with EU regulation: The statements in this document shall not be considered as an objective or independent explanation of the matters. Please note that this document (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research, and (b) is not subject to any prohibition on dealing ahead of the dissemination or publication of investment research.
DISCLOSURE: OPTIONS TRADING
Options involve risk and are not suitable for all investors. For more information read the “Characteristics and Risks of Standardized Options” also known as the options disclosure document (ODD). To receive a copy of the ODD call 312-542-6901.Multiple leg strategies, including spreads, will incur multiple commission charges.
